The independent source for health policy research, polling, and news.
1-20 of 706 results
At least 2 million seniors will receive notice this fall that their Medicare Advantage plans will disappear at year’s end, some without a comparable alternative. Here’s a look at this increasingly common problem with Medicare Advantage, and what it says about Medicare as a whole.
Some states have considered barring companies that own a PBM from also owning brick-and-mortar pharmacies, as CVS does. Two states have followed through. A similar proposal at the federal level has gained prominent sponsors, aligning conservative, business-friendly Republicans with Democrats traditionally more open to government regulation.
“Brain cancer” or “H4 G34-mutant”? As knowledge about genetics advances, some doctors say cancers should be defined by their mutations, not the tissues where they manifest.
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
The new Medicare GLP-1 Bridge program promises eligible beneficiaries access to popular weight loss drugs for as little as $50 a month. But for some, having the very medical conditions these drugs are approved to treat means they don't qualify for the discount.
With his online pharmacy, Mark Cuban changed how generic drugs are sold — and he has thoughts about how to fix the healthcare system. The billionaire businessman talks to KFF Health News’ Julie Rovner to answer the question: “How Would You Fix It?”
Patients and researchers point to evidence that many cancer drug dosages are excessive, and that reducing the amount and frequency could save billions of dollars and prevent some of the worst side effects.
California is the first to launch state-branded insulin as Gov. Gavin Newsom tries to disrupt the pharmaceutical industry. But the new CalRx drug label has been slow to reach pharmacies and patients.
Bill Cassidy of Louisiana chairs the Senate’s health committee. In an interview with KFF Health News’ Julie Rovner, he discusses the drug supply, his proposal to defray out-of-pocket costs, and his controversial vote to confirm Robert F. Kennedy Jr. as health secretary.
Drugmakers provide financial assistance to help patients afford increasingly expensive medications. But some insurers do not count those payments toward a plan’s deductible or out-of-pocket maximum and make patients pay instead.
Thousands of people who had a Medicare drug plan with zero-dollar premiums last year got small premium increases this year — and didn’t know it. They were dropped from their coverage for failing to pay amounts as little as $8, and most can’t get it again until 2027.
Margaret Hvatum ended up in the hospital after her insurer denied coverage of a medicine she relies on to boost her immune system. Hvatum got entangled in the preapproval process, which the insurance industry has vowed to improve.
If your doctor prescribes a GLP-1 medication for weight loss but your insurance won’t cover it, you have options.
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded. Meanwhile, researchers and doctors are concerned that some of these online companies aren't properly screening or monitoring patients. “It gives a black eye to telemedicine,” one researcher said.
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
KFF Health News journalists made the rounds on national media recently to discuss topical stories. Here’s a collection of their appearances.
For all of President Donald Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.
The new TrumpRx program relies partly on connecting consumers with discount coupons offered by drugmakers. For insured patients, though, using a coupon can prove dicey.
It may soon get easier for millions of people with Medicare to get discounted GLP-1 drugs for weight loss.
In “Hikma v. Amarin,” the Supreme Court’s decision could affect how quickly generic versions of brand-name medicines come to market.
© 2026 KFF